Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drugs Cost Patients And Payers 189% More In Hospitals vs. Physician Offices – IMS

This article was originally published in The Pink Sheet Daily

Executive Summary

Differences in covered costs were greatest for Avastin, Lemtrada, Perjeta and Rituxan, among 10 commonly prescribed drugs studied, IMS found. Patient cost sharing was an average $134 higher per dose in hospitals.

You may also be interested in...



BIO Targets 340B Hospital Acquisitions Of Oncology Practices In Study

In an effort to support its claim that the 340B drug discount program is being used by hospitals to generate profits, the Biotechnology Industry Organization released a study finding use of 340B drugs at physician-based oncology practices grew significantly after they were acquired by hospitals.

340B Lobby Group Seeks Bill Changing Hospital Eligibility For Discount Drugs

A group supported by drug manufacturers and pharmacy benefit managers – the Alliance for Integrity and Reform of 340B – is pushing Congress to alter how hospitals qualify for discounted drugs under the 340B program.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077287

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel